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The Efficacy of the EORTC Scoring System and Risk Tables for the 
Prediction of Recurrence and Progression of Non-Muscle-Invasive 
Bladder Cancer after Intravesical Bacillus Calmette-Guerin 
Instillation
Kyung Won Seo, Byung Hoon Kim, Choal Hee Park, Chun Il Kim, Hyuk Soo Chang
Department of Urology, Keimyung University School of Medicine, Daegu, Korea
Purpose: The European Organization for Research and Treatment of Cancer (EORTC) 
scoring system and risk table were introduced in the 2008 European Association of 
Urology guidelines on TaT1 bladder cancer. We compared the recurrence and pro-
gression rate between EORTC risk tables and author’s patients who underwent tran-
surethral resection of bladder cancer (TURB) following intravesical Bacillus 
Calmette-Guerin (BCG) instillation.
Materials and Methods: The medical records of 251 patients who underwent TURB and 
were diagnosed with non-muscle-invasive bladder cancer from l993 to 2007 were 
analyzed. The patients were divided into 2 groups: the recurrence group and the pro-
gression group. According to the EORTC scoring system, the patients in each group 
were categorized in terms of number of tumors, tumor size, prior recurrence rate, T cat-
egory, carcinoma in situ, and pathologic grade and the scores were summed. According 
to the summed scores, the recurrence group and the progression group were divided 
into 3 subgroups: low, intermediate, and high risk, respectively. The recurrence rate 
and progression rate of each group were compared with the EORTC risk tables.
Results: The recurrence rate and progression rate were almost similar to the EORTC 
risk tables. However, the recurrence rate was low in the intermediate-risk group.
Conclusions: Clinical utilization of the EORTC scoring system and risk tables is very 
effective in predicting the recurrence and progression of non-muscle-invasive bladder 
cancer and in selecting treatment.
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INTRODUCTION
Transitional epithelial cell tumors of the bladder are the 
malignant tumors with the highest prevalence in the uri-
nary system in our country, and around 70% of them are 
diagnosed as non-muscle-invasive bladder cancer [1,2]. 
Non-muscle-invasive bladder cancer recurs in 48% to 70% 
of patients after transurethral bladder tumor resections, 
and 10% to 48% of these patients progress into infiltrative 
cancer [2-4]. To prevent this, diverse drugs including 
Bacillus Calmette-Guerin (BCG) are injected into the blad-
der after transurethral resections, and many studies have 
been conducted to develop scales to predict the recurrence 
and progression of non-muscle-invasive bladder cancer 
[5-10].
　The European Organization for Research and Treat-
ment of Cancer (EORTC) scoring system (Appendix 1) was 
introduced in 2008 in the European Association of Urology 
(EAU) guidelines on TaT1 bladder cancer. The system is 
a table that scores six clinical and pathological factors that 
are known to be prognostic factors in superficial bladder 
cancer, including the number of tumors, tumor size, prior 
recurrence rate, T category, presence of carcinoma in situ 
(CIS), and grade. The EORTC risk tables (Appendix 2) are 
tables that divide patients into four groups by score and 
three groups by risk (low risk, intermediate risk, and high 
risk) with the sums of the six factors to enable easy pre-
diction of the recurrence and progression of non-muscle-in-Korean J Urol 2010;51:165-170
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TABLE 1. Patient characteristics and recurrence and progression 
rates
Characteristics
No. of 
patients
(%)
No. of
recurrence
(%)
No. of
progression
(%)
Age (years)
　≤65
　＞65
Sex
　Male
　Female
Prior recurrent rate
　Primary
　≤1 rec/year
　＞1 rec/year
No. of tumors
　1
　2-7
　≥8
Tumor size
　＜3 cm
　≥3 cm
T category
　Ta
　T1
Carcinoma in situ
　No
　Yes
Grade
　I
　II
　III
143 (56.9)
108 (43.1)
191 (76.1)
60 (23.9)
224 (89.2)
16 (6.4)
11 (4.4)
62 (24.7)
109 (43.4)
80 (31.9)
155 (61.8)
96 (38.2)
44 (20.1)
175 (79.9)
213 (84.9)
38 (15.1)
61 (24.3)
124 (49.4)
66 (26.3)
55 (38.5)
49 (45.4)
76 (39.8)
28 (46.7)
78 (34.8)
15 (93.8)
11 (100)
10 (16.1)
41 (37.6)
53 (66.3)
55 (35.5)
49 (51.0)
10 (22.7)
80 (45.7)
87 (40.8)
17 (44.7)
23 (37.7)
48 (38.7)
33 (50.0)
24 (16.8)
22 (20.4)
34 (17.8)
12 (20.0)
39 (17.4)
2 (12.5)
5 (45.5)
1 (1.6)
16 (14.7)
29 (36.3)
20 (12.9)
26 (27.1)
3 (6.8)
33 (18.9)
35 (16.4)
11 (28.9)
8 (13.1)
25 (20.1)
13 (19.7)
vasive bladder cancer. These were developed to aid in the 
selection of treatment after performing transurethral 
bladder tumor resections [2].
　We attempted to compare the results of treatment of 
those patients who were diagnosed as having non-mus-
cle-invasive bladder cancer in our hospital and received 
BCG therapy with the recurrence and progression rates 
presented in the EORTC risk tables in order to examine 
differences.
MATERIALS AND METHODS
The medical records of 251 patients who were followed up 
for at least 1 year among those patients who had been diag-
nosed as having non-muscle-invasive bladder cancer after 
undergoing transurethral bladder tumor resections any-
time between 1993 and 2007 and who thus had received 
BCG therapy were retrospectively analyzed. The BCG 
used by the authors was Oncotice
Ⓡ, which contained Tice 
BCG 2-8x10
8 CFU/ml. Intravesical BCG instillation was 
conducted once per week for the first 6 weeks after bladder 
transitional cell cancers were identified in pathological tis-
sue examinations after transurethral resections and then 
once a month for 3 months.
　The number of tumors, tumor size, the prior recurrence 
rate, T category, the presence of CIS, and grade were re-
corded for each patient according to the EORTC scoring 
system (Appendix 1), and the recurrence and progression 
of bladder cancers were examined. The patients were div-
ided into low, intermediate, and high risk groups according 
to the EORTC risk tables (Appendix 2) on the basis of the 
summed scores. The recurrence rate and the progression 
rate of each group were compared with the values pre-
sented in the EORTC risk tables. In addition, the side ef-
fects of BCG therapy were examined.
RESULTS
The average follow-up period was 68.9 months (range, 
12-204 months). The distributions of the number of tumors, 
tumor size, the prior recurrence rate, T category, the pres-
ence of CIS, and grade and the recurrence and progression 
rates by factor are shown in Table 1.
　Of the total 251 patients, disease recurred in 104 patients 
(41.4%) and progressed in 46 patients (18.3%). The average 
recurrence period was 13.6 months (range, 6-70 months) 
and the average progression period was 57.2 months 
(range, 12-188 months).
　The recurrence rates and progression rates by risk group 
were compared with the EORTC risk tables (Table 2). 
There was no case of recurrence or progression in the low 
risk group with a score of 0. All of the 1-year and 5-year re-
currence rates of the patients were lower than the values 
presented in the EORTC risk tables except for the 1-year 
recurrence rate of the intermediate risk group with re-
currence scores of 5-9, which was 37.9% and thus almost 
the same as the value of 38% in the EORTC risk table. With 
regard to progression rates, 1-year progression rates in the 
intermediate risk group with scores of 2-6 and in the high 
risk group with scores of 7-13 were higher than those in the 
EORTC risk tables (1% vs. 1.8% and 5% vs. 7.8%, re-
spectively), whereas the rate in the high risk group with 
scores of 14-23 in the EORTC risk table was 17% and that 
in our patients was 11.4%. Thus, the rate was lower in our 
patients. As for the 5-year progression rates, the rate in the 
high risk group with scores of 7-13 was higher in our pa-
tients (20.8% vs. 17%), whereas in the intermediate risk 
group with scores of 2-6 and in the high risk group with 
scores of 14-23, the rates were lower in our patients (3.5 % 
vs. 6% and 34.4% vs. 45%, respectively).
　Side effects of BCG therapy appeared in 32 patients 
(13%). The symptoms included bladder-irritating symp-
toms such as urinary frequency, dysuria, burning sensa-
tion, and nocturia and symptoms of lower abdominal pain, 
temporary hematuria, fatigue, chill, and fever. No serious 
complications such as systemic sepsis developed in any 
case.Korean J Urol 2010;51:165-170
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TABLE 2. Comparison of recurrence and progression rates according to total scores of both groups
Recurrence score
Probability of recurrence
at 1 year %
(No. of recurrence/Total No.)
Probability of recurrence
at 5 years %
(No. of recurrence/Total No.)
Recurrence
risk group
EORTC risk tables Author’s results EORTC risk tables  Author’s results
0
1-4
5-9
10-17
15
24
38
61
 0 (0/1)
9.2 (7/76)
37.9 (47/124)
50 (25/50)
31
46
62
78
 0 (0/1)
13.2 (10/76)
46.8 (58/124)
 72 (36/50)
Low risk
Intermediate risk
High risk
Progression score
Probability of progression
at 1 year %
(No. of progression/Total No.)
Probability of progression
at 5 years %
(No. of progression/Total No.)
Progression
risk group
EORTC risk tables Author’s results EORTC risk tables Author’s results
0
2-6
7-13
14-23
0.2
1
5
17
 0 (0/5)
1.8 (1/57)
7.8 (12/154)
11.4 (4/35)
0.8
6
17
45
0 (0/5)
3.5 (2/57)
20.8 (32/154)
34.3 (12/35)
Low risk
Intermediate risk
High risk
EORTC: European organization for research and treatment of cancer
DISCUSSION
Non-muscle-invasive bladder cancer shows quite diverse 
natural histories and prognoses. It sometimes shows re-
peated superficial recurrences, but in some cases, it pro-
gresses into infiltrative or metastatic cancer despite di-
verse treatments. Many studies have been conducted to 
predict the recurrence and progression of non-muscle-in-
vasive bladder cancer. The involved factors known so far 
include clinicopathologic factors, such as the size of the tu-
mor, the degree of infiltration of the tumor, and the degree 
of differentiation of the tumor; DNA evaluation using chro-
mosome markers and flow cytometry; and molecular bio-
logical markers such as tumor surface antigens (ABO, T, 
Lewis Ag), tumor-related antigens including Ɓ-2 micro-
globulin, and tumor genes including H-ras and p53 cell cy-
cle regulatory protein [11-15]. However, authors report the 
prognostic importance of these multiple factors differently 
[5-15], and no certain method to predict prognosis has yet 
been found.
　The EORTC scoring system and the risk tables of the 
2008 EAU guidelines were made to aid future selections of 
treatments by providing a method to simply predict the 
possibility of recurrence and progression of non-muscle-in-
vasive bladder cancer by using factors that can be easily 
applied clinically. The EORTC scoring system gives scores 
to factors such as the number of tumors, tumor size, the pri-
or recurrence rate, T category, the presence of CIS, and 
grade and sums the scores. In the EORTC scoring system, 
different scores are used to predict recurrence rates and to 
predict progression rates. Factors that more severely af-
fected recurrence in the EORTC trials were the number of 
tumors, the prior recurrence rate, and the degree of differ-
entiation of tumor cells (WHO grade II), and thus higher 
scores were given to these factors. Factors that more se-
verely affected progression were T category, existence of 
CIS, and the degree of differentiation of tumor cells (WHO 
grade III), and these factors were given relatively higher 
scores for predicting progression compared with other 
factors. The size of the tumors was shown to affect both re-
currence and progression and thus the same score was giv-
en [2].
　When we compared the recurrence rates in the EORTC 
risk tables with the results in our patients, the 1-year re-
currence rate (9.2% vs. 24%) and the 5-year recurrence rate 
(13.2% vs. 46%) in the intermediate risk group with a re-
currence score of 1 to 4 were lower in our patients. In addi-
tion, in the intermediate risk group with a recurrence score 
of 5 to 9, the 5-year recurrence rate was lower in our patients 
(46.8% vs. 62%). This result is suggested to be because of 
differences in subject groups. With regard to the population 
of the EORTC trial, BCG therapy was carried out in only 
5.9% of the population and intravesical chemotherapy 
(thiotepa, epirubicin, mitomycin C, or pyridoxine) was car-
ried out in the remaining patients. On the other hand, the 
subjects in our study received only BCG therapy, and this 
is considered to be the reason for the low recurrence rates 
and progression rates.
　In general, treatment methods have been established for 
patients with low risks such as a single tumor, category Ta, 
and WHO grade I or patients with high risks such as CIS 
and WHO grade III; however, there is no clearly defined 
treatment method for patients with intermediate risks. In 
the past, intravesical chemotherapy was mainly used, but 
recently, BCG therapy has been preferred and many re-
ports indicate that BCG therapy is more effective in pre-
venting recurrences than is intravesical chemotherapy 
[16-18]. In a multicenter study conducted with 2,820 non- Korean J Urol 2010;51:165-170
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muscle-invasive bladder cancer patients, Malmström et al 
reported that, of 1,983 patients with intermediate risks, 
49% were in a mitomycin-C therapy group and 51% were 
in a BCG therapy group, and the risk of recurrence de-
creased by 32% in the patients who received BCG main-
tenance therapy [19]. In a study by Böhle et al, of 2,749 pa-
tients, 1,421 patients received BCG therapy and 1,328 pa-
tients received mitomycin-C therapy, and the rate of re-
currence in the BCG therapy group was 38.6%, which was 
lower than that in the mitomycin-C therapy group, which 
was 46.4% [20]. Also, in an analysis that classified the pa-
tients by risk groups, BCG was shown to be more effective 
than mitomycin-C in preventing recurrences in patients 
with intermediate or high risks; thus, it was emphasized 
that BCG maintenance therapy was an independent factor 
in preventing recurrences [20]. Cheng et al compared the 
10-year recurrence-free survival rate between 102 non- 
muscle-invasive bladder cancer patients in a BCG therapy 
group and 107 patients in a epirubicin therapy group and 
reported a lower recurrence-free survival rate in the BCG 
therapy group than in the epirubicin therapy group, with 
a rate of 61% in the BCG therapy group and 32% in the epi-
rubicin therapy group [21].
　In the comparison of progression rates, there was no defi-
nite difference between the values presented in the EORTC 
risk tables and our results. In previous studies that com-
pared BCG therapy and intravesical chemotherapy, many 
results indicating that BCG therapy and intravesical che-
motherapy do not differ in preventing the progression of 
bladder cancer have been reported. Through a multicenter 
study, Shelley et al compared the non-muscle-invasive 
bladder cancer progression rate of a BCG therapy group 
with that of a mitomycin-C therapy group and reported 
that there was no difference between the two groups with 
a log risk rate of 0.044 (p=0.16) [22]. Also, Lundholm et al 
reported that non-muscle-invasive bladder cancer pro-
gressed in 12.2% of a BCG therapy group and 13% of a mito-
mycin-C therapy group and that there was thus no differ-
ence between BCG therapy and mitomycin-C therapy [23].
　Although it is known that BCG therapy is helpful in pre-
venting recurrences, doctors hesitate to use BCG therapy 
due to complications. The symptoms include urinary fre-
quency, burning sensation, light muscle pain, and low fe-
ver; the most dangerous complications are systemic sepsis 
and hypersensitivity reactions, which are characterized by 
chill, fever, and progressive multiorgan damage. However, 
many studies suggest that the side effects of BCG therapy 
are minor. Lamm et al reported that, of 2,602 patients who 
received BCG therapy, less than 5% experienced side ef-
fects, and the symptoms were minor in most cases. The in-
cidence of hypersensitivity reactions, which is a dangerous 
complication, has been reduced greatly from 0.4% in the 
early days to around 0.007% currently [24,25]. In this 
study, treatments were stopped due to complications in 5 
patients out of 251 (2%), but there was no case in which seri-
ous complications like systemic sepsis developed. In gen-
eral, compliance with BCG therapy was quite high and 
complications were shown to be minor. Thus, there was no 
problem in proceeding with the BCG maintenance therapy.
　There are several limitations to simply comparing our re-
sults with the values in the EORTC risk tables of the EAU 
guidelines. First, the patient groups were treated mostly 
by intravesical chemotherapy in the EAU guidelines, 
whereas our patient groups consisted only of patients 
treated with BCG therapy. Because of this difference, pa-
tients were evenly distributed in the low, intermediate, 
and high risk groups in the EAU guidelines, whereas the 
number of patients in the low risk group was relatively 
small in our study. Second, it is difficult to concretely verify 
statistics because our study data were compared with data 
from the EORTC study, which was a multicenter study. 
Due to differences in subject patient groups, treatment 
methods, and the fact that the statistical support is not suf-
ficient, it is not quite reasonable to directly compare the re-
sults of our study with the results of the EAU guidelines. 
However, it is noteworthy that our study compared and 
verified the EORTC scoring system and risk tables pre-
sented by the 2008 EAU guidelines on TaT1 Bladder 
Cancer for the first time in Korea. Also, because our patient 
groups were treated by BCG only, it is possible to compare 
the effect of BCG therapy with the effects of other treat-
ment methods. The results of this study will therefore pro-
vide meaningful data for supporting the superiority of BCG 
therapy in typical intermediate risk groups as shown in 
previous studies.
CONCLUSIONS
The recurrence and progression of non-muscle-invasive 
bladder cancer in patients in our hospital were compared 
with those in the EORTC risk tables using the EORTC scor-
ing system presented by the 2008 EAU guidelines on TaT1 
Bladder Cancer. The results suggest that clinical uti-
lization of the EORTC scoring system will be useful in pre-
dicting the recurrence and progression of non-muscle-in-
vasive bladder cancer and in selecting treatments.
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APPENDIX 1. EORTC scoring system: weights used to calculate the recurrence and progression scores
Factor Recurrence Progression
No. of tumors
　Single
　2 to 7
　≥8
Tumor size
　＜3 cm
　≥3 cm
Prior recurrence rate
　Primary
　≤1 recurrence/year
　＞1 recurrence/year
T category
　Ta
　T1
Carcinoma in situ
　No
　Yes
Grade
　1
　2
　3
0
3
6
0
3
0
2
4
0
1
0
1
0
1
2
0
3
3
0
3
0
2
2
0
4
0
6
0
0
5
Total score 0-17 0-23
EORTC: European organization for research and treatment of cancer
APPENDIX 2. EORTC risk tables: probability of recurrence and progression according to total score
Recurrence score
Probability of recurrence
at 1 year (%) (95% CI)
Probability of recurrence
at 5 years (%) (95% CI)
Recurrence
risk group
0
1-4
5-9
10-17
15 (10-19)
24 (21-26)
38 (35-41)
61 (55-67)
31 (24-37)
46 (42-49)
62 (58-65)
78 (73-84)
Low risk
Intermediate risk
High risk
Progression score
Probability of progression
at 1 year (%) (95% CI)
Probability of progression
at 5 years (%) (95% CI)
Progression
risk group
0
2-6
7-13
14-23
0.2 (0-0.7)
      1 (0.4-1.6)
5 (4-7)
  17 (10-24)
0.8 (0-1.7)
6 (5-8)
17 (14-20)
45 (35-55)
Low risk
Intermediate risk
High risk
EORTC: European organization for research and treatment of cancer